SPL to present DEP radiotheranostics at Wilsons Conference (ASX Announcement)
Starpharma today announces that it will present at the Wilsons Drug and Device Conference tomorrow, 27 October 2023, at 10:00 AM AEST.
Starpharma receives $7.2 million R&D Tax Incentive refund (ASX Announcement)
Starpharma today announces it has received a $7.2 million research and development (R&D) tax incentive refund under the Australian Federal Government’s R&D Tax Incentive scheme.
DEP® irinotecan IO/PARP combination data presented at AACR (ASX Announcement)
Starpharma (ASX: SPL, OTCQX: SPHRY) today provides a copy of the DEP® irinotecan combination data poster, showcasing the recently announced1 data for DEP® irinotecan in combination with leading anticancer therapies, including immuno-oncology (IO) agents, in human colorectal cancer (CRC) models.
DEP® irinotecan clinical data presented at AACR meeting (ASX Announcement)
Starpharma today provides a copy of the DEP® irinotecan clinical poster, highlighting the recently announced1 positive interim clinical data from Starpharma’s Phase 1/2 clinical trial, which demonstrated durable anti-tumour responses in advanced colorectal cancer (CRC) and platinum-resistant/refractory ovarian cancer.
DEP® theranostic presented at international oncology meeting (ASX Announcement)
Starpharma today provides a copy of the poster that showcases the results from a study of DEP® HER2-zirconium, Starpharma’s HER2-targeted radiodiagnostic candidate, which demonstrated a favourable biodistribution profile, with excellent imaging contrast between tumour and normal tissues, as well as rapid uptake and high levels of tumour accumulation in a HER2+ breast cancer model.